immunoassays: extraction methods for microsamples | Neoteryx

As the COVID-19 crisis continues to wreak havoc on public health and the world economy, all eyes are on our research scientists in the hope they can develop more effective SARS-CoV-2 tests and insightful data. To do this, laboratories around the globe are rapidly developing immunoassays for COVID-19. Several labs have successfully on-boarded Mitra® microsampling devices with VAMS® technology from Neoteryx to conduct testing on a variety of analytes, including immunoglobulins. A question raised by researchers considering this technology and using dried specimen samples is: How can I optimize extraction methods to achieve strong signals and stable extracts when running an immunoassay?
To answer this question, we looked at several study papers in peer-reviewed publications to provide a summary of research studies using extraction methodology for Mitra remote sampling devices in ligand binding assays.
For details, you can download our Tech Brief: Extraction Methods Using Mitra® from the Current Literature here: www.neoteryx.c...
WEBSITE:
www.neoteryx.com/
Mitra is an exempt medical device in the US, CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, and registered with Health Canada. It is intended as a specimen collector and for the storage and transport of biological fluids. Use of the Mitra device with blood for diagnostic applications is limited to certain countries and, in the US, for research and non-diagnostic purposes only.